Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells - TREAT-ME-1 - a phase I, first in human, first in class trial

PURPOSE: This phase I, first in human, first in class clinical study aimed at evaluating the safety, tolerability and efficacy of treatment with genetically modified mesenchymal stromal cells (MSC) in combination with ganciclovir (GCV). MSC_apceth_101 are genetically modified autologous MSCs used as...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: von Einem, Jobst C., Peter, Sylvia, Günther, Christine, Volk, Hans-Dieter, Grütz, Gerald, Salat, Christoph, Stoetzer, Oliver, Nelson, Peter J., Michl, Marlies, Modest, Dominik P., Holch, Julian W., Angele, Martin, Bruns, Christiane, Niess, Hanno, Heinemann, Volker
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2017
Sujets:
Priority Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5655186/
https://ncbi.nlm.nih.gov/pubmed/29113291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.20964
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires